Why is the ResApp share price lifting today?

Progress on a takeover bid for the company has been announced.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Shareholders have given the green light on a takeover proposal from Pfizer
  • The court must approve it for the deal to proceed
  • The deal is expected to close on the 23rd of September

The ResApp Health Ltd (ASX: RAP) share price is in the green today as investors digest the latest news on Pfizer's proposed takeover bid.

Shares in the ASX healthcare company are up 0.98%, trading at 21 cents at the time of writing after shareholders yesterday approved the scheme of arrangement for Pfizer to acquire 100% of ResApp's shares.

ResMed advised the next step of the takeover process would involve a second court hearing at the Supreme Court of New South Wales to be held on Tuesday next week.

For the bid to be accepted, the Supreme Court must first approve it on the condition that it's in the best interest of ResApp shareholders. Also, any remaining conditions must be either satisfied or waived before the hearing.

If these conditions are met, the deal is expected to complete on 23 September. The last date that ResApp shares will trade on the ASX will be Wednesday, 14 September.

Pfizer upgraded its bid to 20.8 cents per share on Saturday last week, up from 14.6 cents per share.

That puts ResApp's valuation in the $198.8 million ballpark at the time of writing.

A group of people in a corporate setting do a collective high five.

Image source: Getty Images

ResApp share price snapshot

The ResApp share price is up a stunning 195.7% year to date. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is down 10.77% over the same period.

The company's market capitalisation is $178.3 million at the time of writing.

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Game over? ASX biotech stock crashes 90% on big bad news

Is it game over for this stock? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Should you buy low on these ASX healthcare stocks?

These two stocks could be poised for a bounce back.

Read more »

Woman with a concerned look on her face holding a credit card and smartphone.
Healthcare Shares

What on earth's going on with the CSL share price?

The company has long been one of the highest-quality businesses on the ASX, which makes its recent decline even more…

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

These ASX healthcare stocks are set to thrive as the population ages

A powerful demographic tailwind, but can they execute?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

This drug developer could have huge upside, brokers say

Gains of more than 100% are not off the cards apparently.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

Four ASX healthcare stocks which are looking cheap

These companies could be just what the doctor ordered.

Read more »

Two health workers taking a break.
Healthcare Shares

Bell Potter is tipping this exciting ASX healthcare stock to rise 80%

An important clinical trial announcement is good news for this healthcare stock.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

Is this one of the best ASX 200 stocks money can buy?

High margins, strong growth, and global expansion have helped this ASX company stand out to me.

Read more »